The interFACE Lab The Interactive and Functional Assessment of Communication and Emotion (InterFACE) Center is a natural observation laboratory designed to research emotional and behavioral deficits in people with neurological,… Read More
TrackTBI Investigator: Richard Rodgers, MD TRACK-TBI: The multicenter Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study aims to improve success of clinical trial design through the collection and analysis of… Read More
Training to Reconnect with emotional awareness therapy (TREAT) Investigators: Dawn Neumann, Flora Hammond The purpose of this study is to teach participants with traumatic brain injury to develop better emotional… Read More
Avanir Study Sheryl Katta-Charles MD, Principal Investigator A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability or AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for… Read More
Long-Term, Prospective, Non-Interventional Study Monitoring Safety and Training in Patients with Spinal Cord Injuries and Their Trained Companions Recently Initiated with the ReWalk™ Personal Device. Flora Hammond, MD (PI), funded… Read More
Multicenter Evaluation of Memory Remediation after TBI with Donepezil (MEMRI-TBI-D Study)
March 10, 2015
Flora Hammond, MD (PI); Funded by National Institute on Disability and Rehabilitation Research (NIDRR).
This study is a four-site, randomized, parallel design, double-blind, placebo-controlled, 10-week trial that will evaluate the effect of donepezil on treatment for functionally important verbal memory problems among 160 individuals (age 18-60 years) who sustained a complicated mild, moderate, or severe non-penetrating TBI six to 36 months prior to study participation.
The primary aims of this study are to evaluate the effect of donepezil on verbal memory and to assess the effects of donepezil on memory-related everyday function in the target population (i.e., persons age 18-60 years with clinically important verbal memory impairments during the subacute or chronic period (i.e., 6-36 months after complicated mild, moderate, or severe non-penetrating TBI). The study also will acquire data that inform on the effects of donepezil on other aspects of cognition (i.e., attention, processing speed, executive function), neuropsychiatric symptoms, community participation, and quality of life in this population as well as on caregiver burden.
Contact: Christy Sargent at firstname.lastname@example.org or at (317) 963-7448